Aldeyra Therapeutics, Inc. (ALDX)
NASDAQ: ALDX · Real-Time Price · USD
5.53
+0.44 (8.64%)
At close: Feb 6, 2026, 4:00 PM EST
5.53
0.00 (0.00%)
After-hours: Feb 6, 2026, 4:00 PM EST
Aldeyra Therapeutics Employees
Aldeyra Therapeutics had 8 employees as of September 30, 2025. The number of employees decreased by 1 or -11.11% compared to the same quarter last year.
Employees
8
Change
-1
Growth
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$5,399,240
Market Cap
332.70M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 8 | -1 | -11.11% |
| Jun 30, 2025 | 8 | -2 | -20.00% |
| Mar 31, 2025 | 8 | -2 | -20.00% |
| Dec 31, 2024 | 9 | -1 | -10.00% |
| Sep 30, 2024 | 9 | -3 | -25.00% |
| Jun 30, 2024 | 10 | -5 | -33.33% |
| Mar 31, 2024 | 10 | -5 | -33.33% |
| Dec 31, 2023 | 10 | -5 | -33.33% |
| Sep 30, 2023 | 12 | -3 | -20.00% |
| Jun 30, 2023 | 15 | 1 | 7.14% |
| Mar 31, 2023 | 15 | 1 | 7.14% |
| Dec 31, 2022 | 15 | 3 | 25.00% |
| Sep 30, 2022 | 15 | 4 | 36.36% |
| Jun 30, 2022 | 14 | 4 | 40.00% |
| Mar 31, 2022 | 14 | 6 | 75.00% |
| Dec 31, 2021 | 12 | 1 | 9.09% |
| Sep 30, 2021 | 11 | 0 | - |
| Jun 30, 2021 | 10 | 0 | - |
| Mar 31, 2021 | 8 | -7 | -46.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Rocket Pharmaceuticals | 299 |
| Puma Biotechnology | 172 |
| X4 Pharmaceuticals | 143 |
| Foghorn Therapeutics | 112 |
| Aura Biosciences | 109 |
| Neumora Therapeutics | 95 |
| Atea Pharmaceuticals | 56 |
| Immuneering | 54 |
ALDX News
- 5 weeks ago - Aldeyra Therapeutics: Reproxalap's March 2026 FDA Decision Is The Defining Catalyst - Seeking Alpha
- 7 weeks ago - Aldeyra Therapeutics, Inc. (ALDX) Discusses PDUFA Target Action Date Extension for Reproxalap in Dry Eye Disease Transcript - Seeking Alpha
- 7 weeks ago - Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease - Business Wire
- 3 months ago - Aldeyra Therapeutics, Inc. (ALDX) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry Eye Transcript - Seeking Alpha
- 3 months ago - Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast - Business Wire
- 3 months ago - Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London - Business Wire
- 3 months ago - Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET - Business Wire
- 3 months ago - Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules - Business Wire